Biotech companies see China as one of the biggest healthcare opportunities, but would need partnerships before approaching the market, a new report suggests.
New tariffs on goods coming from China could hit the US pharmaceutical industry, according to a new analysis – and even undermine President Trump’s pledge to drive down the price of medicin
China has become more accepting of Western medicines and sees the value of a strong patenting process, opening the door for more foreign trade and mutual benefits.
Innovative channels now take 60% of share compared with traditional channels for medical communication in China, reports Adele Li of Kantar Health, and doctors’ willingness to engage with pharma companies online is a cause for optimism for those working in the region. Read the full article in the latest edition of pharmaphorum's Deep Dive: Digital magazine.